TNFRSF9 and neoplasm: However, the addition of anti-4-1BB Abs to the E7 DNA vaccine regimen (E7 DNA vaccines+IL-2 cDNA) increased the tumor cure rate from 27% to 67%, a 9.6-fold increase in tumor cure rates following the addition of both IL-2 cDNA and anti-4-1BB Abs.